Aarey Drugs & Pharmaceuticals
103.85
+1.13(+1.10%)
Market Cap₹294.46 Cr
PE Ratio75.90
IndustryHealthcare
Company Performance:
1D+1.10%
1M+16.67%
6M+104.63%
1Y+25.36%
5Y+186.88%
View Company Insightsright
More news about Aarey Drugs & Pharmaceuticals
11Feb 26
Aarey Drugs & Pharmaceuticals Reports Q3FY26 Results with Revenue Decline
Aarey Drugs & Pharmaceuticals Limited reported Q3FY26 results with revenue from operations declining 27.9% to ₹9,642.63 lakhs from ₹13,378.86 lakhs in Q3FY25. Net profit decreased 20.7% to ₹56.95 lakhs compared to ₹71.80 lakhs in the previous year quarter. Nine-month performance also showed declining trends with total income falling 21.4% to ₹28,932.32 lakhs and net profit dropping 16.6% to ₹296.49 lakhs. The company purchased fixed assets during the period that are not yet operational.
 no imag found
06Sept 25
Aarey Drugs & Pharmaceuticals Announces Share Capital Increase and Preferential Issue Plans
Aarey Drugs & Pharmaceuticals Ltd has approved an increase in Authorised Share Capital from Rs. 255.00 crores to Rs. 355.00 crores. The company plans a preferential issue of 50 lakh equity shares and 50 lakh warrants convertible into equity shares. These proposals are subject to shareholder approval at the upcoming AGM on September 5, 2023. The company's recent financial results show a 17.72% increase in revenue to Rs. 473.94 crores, but a 10.85% decrease in net profit to Rs. 4.19 crores.
 no imag found
13Aug 25
Aarey Drugs & Pharmaceuticals Reports Q1 Results: Revenue Dips, Profit Rises
Aarey Drugs & Pharmaceuticals released its Q1 FY26 unaudited financial results, showing a 19.48% decrease in total income to Rs. 1,037.60 lakhs. Despite lower revenue, profit after tax increased by 10.81% to Rs. 13.73 lakhs. Basic EPS improved by 9.09% to Rs. 0.48. The company maintained profitability despite revenue decline, suggesting effective cost management. The results were approved by the Board of Directors and reviewed by auditors.
 no imag found
1 Year Returns:+25.36%
Industry Peers
Sun Pharmaceutical
1,801.00
(-0.86%)
Divis Laboratories
9,249.00
(-0.46%)
Torrent Pharmaceuticals
4,767.30
(-0.68%)
Zydus Life Science
1,145.70
(-1.40%)
Cipla
1,344.00
(-0.15%)
Laurus Labs
1,984.00
(+0.20%)
Mankind Pharma
2,535.00
(+1.25%)
Dr Reddys Laboratories
1,206.20
(-2.17%)
Aurobindo Pharma
1,676.80
(+0.29%)
Lupin
2,031.20
(+0.05%)